
382: Biotech's year in review
The Readout Loud
00:00
Is biotech back? Bruce's view
Bruce argues biotech is back, citing strong summer-to-fall stock outperformance and clinical-stage gains.
Play episode from 14:39
Transcript

Bruce argues biotech is back, citing strong summer-to-fall stock outperformance and clinical-stage gains.